Two German biotech companies are cooperating in a personalized medicine project to develop a predominantly tissue-based biomarker strategy for the treatment of solid cancers with cellular and / or gene therapeutics.

The partnership will exploit the complimentary assets of apceth GmbH & Co. KG (Munich, Germany), and Indivumed GmbH, (Hamburg, Germany). apceth is known for its development and clinical application of pioneering stem cell and gene therapies, particularly for the treatment of malignant diseases. Indivumed maintains a comprehensive tumor database and high-quality biobank for the development of new cancer diagnostics and therapies, and provides state-of-the-art services for biomarker discovery based on viable primary human biospecimens.

The goal of the new project is to predict the response to targeted cellular/ gene therapy in different cancer types and to stratify patients to provide a more individualized cancer treatment with apceth’s innovative cell and cell-based gene therapeutics.

The partners have indicated that the combination of apceth’s therapeutic approach and Indivumed’s biomarker platform has the potential to drive future cancer therapeutics and pharmaceutical innovation, thereby making the promises for personalized medicine a reality.

Related Links:
apceth GmbH & Co. KG
Indivumed GmbH